Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Poll|Articles|September 6, 2023
POLL: What is an Ideal Initial Treatment for Low-Risk Basal Cell Carcinoma?
Author(s)Dermatology Times Staff
Click here to answer this week's skin cancer poll.
Advertisement
POLL: What is an ideal initial treatment for low-risk basal cell carcinoma?
Share your experiences with us and any additional basal cell carcinoma treatment pearls by emailing
For more insights on basal cell carcinoma management, read our recent Frontline Forum series, "
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
Advertisement
Advertisement